Heron Therapeutics is trading at $0.36, down 5.36%, with no clear company-specific catalyst identified for the October 8 decline.
- Heron’s news page lists its Q2 results, dated August 10, as its latest release.
- The company withdrew its 2026 financial guidance in August, but available reporting does not establish that as the cause of the session’s move.
- Market indexes showed modest declines, making broader-market pressure possible but unconfirmed.